Actively Recruiting
Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis
Led by Sarah Schiebler · Updated on 2024-12-16
90
Participants Needed
1
Research Sites
151 weeks
Total Duration
On this page
Sponsors
S
Sarah Schiebler
Lead Sponsor
U
University of Zurich
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a distinct disease entity with an estimated prevalence of 0.3-0.7% and more common in women (3:1 ratio). It can be diagnosed according to the Institute of Medicine (IOM) 2015 consensus definition using 3 major criteria and one of 2 minor criteria. Diagnosis requires that the patient have the following three symptoms: 1. A substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities that persists for more than 6 months and is accompanied by fatigue, which is often profound, is of new or definite onset (not lifelong), is not the result of ongoing excessive exertion, and is not substantially alleviated by rest, 2. Post-exertional malaise,\* and 3. Unrefreshing sleep\* At least one of the two following manifestations is also required: 1. Cognitive impairment\* or 2. Orthostatic intolerance Note\* Frequency and severity of symptoms should be assessed. The diagnosis of ME/CFS should be questioned if patients do not have these symptoms at least half of the time with moderate, substantial, or severe intensity. Currently, individually tailored therapy with emphasis on cognitive behavioral therapy and graduated activity therapy is considered the therapy of first choice, although their effectiveness has been critically questioned in recent years. There are often frustrating treatment courses, a larger proportion of partial remissions, a significantly smaller proportion of full remissions and return to work. The study aims to evaluate patients of the outpatient service for chronic fatigue at the Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Switzerland, in the context of a group therapy for the treatment of CFS/ME in respect to the response to different, non-drug based therapeutic procedures and to gain knowledge about the effects of the therapy. The study is a clinical comparative study of therapeutic procedures/interventions without the use of drugs or a medical product. The interventions are Acceptance Commitment Therapy (ACT) and Micro Breaks in Everyday Life (MBEL) adapted to CFS/ME. The collection of biological samples (saliva, blood) and health-related personal data (actigraphy, psychometric data from questionnaires) is associated with minimal risks and burdens.
CONDITIONS
Official Title
Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis for CFS/ME
- Psychiatric clinical stability in the past 3 months
- No diagnostic change to other ICD-10 categories
- No psychiatric inpatient treatments
- No psychiatric emergency treatments
- No suicide attempts
- Possession of internet access
- Sufficient skills to use electronic devices
- Willingness to engage in ACT or MBEL therapeutic procedures
You will not qualify if you...
- Insufficient knowledge of German
- Severe psychiatric disorders (e.g., personality, posttraumatic stress, dissociative, psychotic disorders), intelligence reduction, untreated ADHD, or acute suicidal tendencies
- Untreated or severe internal medicine disorders such as thyroid dysfunction or sleep apnea syndrome
- Cardiovascular diseases like chronic heart failure
- Severe or untreated neurological diseases (e.g., Parkinson's disease, dementia, restless legs syndrome, narcolepsy)
- Alcohol and drug dependence
- Psychopharmacotherapy started in the past 3 months
- Start of other psychotherapy procedures in the last 3 months
- Other parallel therapy methods (e.g., acupuncture, qigong, osteopathy)
- Recent somatic treatments that disrupt sleep, cortisone, or radio-/chemotherapy in the last 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital of Zurich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
S
Sarah Schiebler, MBA, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here